Terms: = Prostate cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Prognosis
35 results:
1. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
2. A Crosstalk Between Castration-Resistant prostate cancer Cells, M2 Macrophages, and NK Cells: Role of the atm-PI3K/AKT-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract] [Full Text] [Related]
3. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
5. Somatic and Germline Variants Affect prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
6. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
[TBL] [Abstract] [Full Text] [Related]
7. Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with prognosis of prostate cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2022 Nov; 11(22):. PubMed ID: 36429046
[TBL] [Abstract] [Full Text] [Related]
8. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
[TBL] [Abstract] [Full Text] [Related]
9. Hypomethylation and the Resultant Overexpressed PARM1: a Biomarker for Poor prognosis of Diffuse Large B-cell Lymphoma.
Cao B; Guo X; Wang B; Wang W; Han D; Zhang W; Zhong K
Discov Med; 2022; 33(168):27-40. PubMed ID: 36274211
[TBL] [Abstract] [Full Text] [Related]
10. ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract] [Full Text] [Related]
11. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract] [Full Text] [Related]
12. Immune Biomarkers in Metastatic Castration-resistant prostate cancer.
Fenor de la Maza MD; Chandran K; Rekowski J; Shui IM; Gurel B; Cross E; Carreira S; Yuan W; Westaby D; Miranda S; Ferreira A; Seed G; Crespo M; Figueiredo I; Bertan C; Gil V; Riisnaes R; Sharp A; Rodrigues DN; Rescigno P; Tunariu N; Liu XQ; Cristescu R; Schloss C; Yap C; de Bono JS
Eur Urol Oncol; 2022 Dec; 5(6):659-667. PubMed ID: 35491356
[TBL] [Abstract] [Full Text] [Related]
13. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
[TBL] [Abstract] [Full Text] [Related]
14. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract] [Full Text] [Related]
15. Deficiency of NEIL3 Enhances the Chemotherapy Resistance of prostate cancer.
Wang Y; Xu L; Shi S; Wu S; Meng R; Chen H; Jiang Z
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921035
[TBL] [Abstract] [Full Text] [Related]
16. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
[TBL] [Abstract] [Full Text] [Related]
17. Kinetics of radium-223 and its effects on survival, proliferation and DNA damage in lymph-node and bone metastatic prostate cancer cell lines.
Marques IA; Abrantes AM; Pires AS; Neves AR; Caramelo FJ; Rodrigues T; Matafome P; Tavares-da-Silva E; Gonçalves AC; Pereira CC; Teixeira JP; Seiça R; Costa G; Figueiredo A; Botelho MF
Int J Radiat Biol; 2021; 97(5):714-726. PubMed ID: 33764249
[TBL] [Abstract] [Full Text] [Related]
18. atm inhibitor KU-55933 induces apoptosis and inhibits motility by blocking GLUT1-mediated glucose uptake in aggressive cancer cells with sustained activation of Akt.
Harris BRE; Zhang Y; Tao J; Shen R; Zhao X; Cleary MP; Wang T; Yang DQ
FASEB J; 2021 Apr; 35(4):e21264. PubMed ID: 33715230
[TBL] [Abstract] [Full Text] [Related]
19. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
20. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.
Hou X; Zhang Y; Han S; Hou B
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649
[TBL] [Abstract] [Full Text] [Related]
[Next]
